AbbVie drops autoimmune candidate, prioritizes Skyrizi and RinvoqBusiness, R&D, TherapeuticsWhile reporting positive third-quarter financials, AbbVie announced it is halting the development of cedirogant (ABBV-157), while also providing updates on Skyrizi, Rinvoq and Humira. Read more October 31, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/04/BioSpaceAbbVie.jpg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-10-31 11:51:252022-10-31 11:51:35AbbVie drops autoimmune candidate, prioritizes Skyrizi and Rinvoq